netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Lenalidomide found 22 matches

Formulary items 4 matches
Non-formulary items 1 match
Sub Section Title / notes 1 match
   
Open monograph to display formulary status BNF Category
  Lenalidomide Malignant disease and immunosuppression - Lenalidomide, pomalidomide, and thalidomide - 08.02.04
  Cytotoxic Drug Carfilzomib  (Kyprolis®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Cytotoxic Drug Daratumumab  (Darzalex®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Pomalidomide  (Imnovid®) Malignant disease and immunosuppression - Lenalidomide, pomalidomide, and thalidomide - 08.02.04
 
Non Formulary BNF Category
  Tafasitamab  (Minjuvi® ) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section Letter sent to healthcare professionals (Nov 2016): lenalidomide (Revlimid▼): new advice about viral reactivation (08.02.04)
link in drug section MHRA Drug Safety Update (Feb 2011): Lenalidomide: risk of thrombosis and thromboembolism (08.02.04)
link in drug section MHRA Drug Safety Update (Jan 2013): Lenalidomide (Revlimid): risk of serious hepatic adverse drug reactions (08.02.04)
link in drug section MHRA Drug Safety Update (Nov 2011): Lenalidomide (Revlimid▼): update on risk of second primary malignancy (08.02.04)
link in drug section NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies (08.02.04)
link in drug section NICE TA27: Lenalidomide with rituximab for previously treated follicular lymphoma (08.02.04)
link in drug section NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (08.02.04)
link in drug section NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (08.01.05)
link in drug section NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (08.02.04)
link in drug section NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (08.02.04)
link in drug section NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma (08.02.04)
link in drug section NICE TA680: Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (08.02.04)
link in drug section NICE TA695: Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (08.01.05)
link in drug section NICE TA870: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (08.01.05)
link in drug section NICE TA883: Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma (08.01.05)
link in drug section NICE TA917: Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable (08.01.05)

SubSection Titles / notes  
Lenalidomide, pomalidomide, and thalidomide - (08.02.04)

 
netFormulary